Introduction {#section1-0269881118760662}
============

Psychotic illnesses have an annual prevalence of around 0.4% of the population and a cost to the economy of £13.5 billion a year in England alone ([@bibr79-0269881118760662]). Early-onset psychosis may herald chronic illness, such as schizophrenia or schizoaffective disorder, with considerable impact on the individual's functioning, social and occupational opportunities. Consequently, better understanding of early psychosis is critical to the development of preventative and treatment strategies. Comorbid cannabis use is a particularly important problem for the clinician treating patients with psychosis, as it is present in around 30--40% of patients with early psychosis, constituting a considerable proportion of their caseload ([@bibr117-0269881118760662]), and is associated with poorer prognosis ([@bibr122-0269881118760662]; [@bibr154-0269881118760662], [@bibr154-0269881118760662], [@bibr155-0269881118760662], [@bibr156-0269881118760662], [@bibr157-0269881118760662]).

This article will restrict itself to the association between cannabis and psychotic disorders. When discussing the association between cannabis and psychosis a clear distinction must be made between several psychosis outcomes: (a) risk of developing enduring psychotic disorder, (b) risk of relapse once a psychotic disorder has developed and (c) the transient psychotomimetic states that cannabis induces ([@bibr116-0269881118760662]). In particular, transient psychotomimetic states are common, self-limiting, non-clinical entities, experienced in around 15% of users ([@bibr177-0269881118760662]); demonstrable in healthy individuals when administered phytocannabinoids ([@bibr48-0269881118760662]), with increased propensity with psychotic disorders or risk of psychosis ([@bibr69-0269881118760662], [@bibr70-0269881118760662]; [@bibr178-0269881118760662]; [@bibr186-0269881118760662]), they are not the focus of this article, wherein we focus on the relationship between cannabis and outcomes related to the development of psychotic disorder and its relapse. In the first section we present a critical review as an overview of the epidemiological association between cannabis and psychotic disorder, and go on to discuss differences between patients with established psychotic disorder who use cannabis and those who do not. In the second section, in order to advance understanding of the neurobiological association of cannabis and psychotic disorder, we undertake a systematic search to delineate whether neurobiological differences exist between groups.

I. Epidemiological understandings to date relating to psychotic disorder {#section2-0269881118760662}
------------------------------------------------------------------------

It is worth bearing in mind, in the discussion that follows, that cannabis is not a homogenous entity and is constituted of a variety of chemical constituents which may have varying and, at times, opposing effects ([@bibr14-0269881118760662]; [@bibr37-0269881118760662]). Particular interest has focused on two plant cannabinoids: (a) Δ-9-tetrahydrocannabinol (THC) which has anxiolytic effects at lower doses, whereas at higher doses typically demonstrates anxiogenic and psychotomimetic effects ([@bibr21-0269881118760662], [@bibr15-0269881118760662], [@bibr18-0269881118760662]), and (b) cannabidiol (CBD), which typically demonstrates anxiolytic properties ([@bibr40-0269881118760662]). Yet there are over 100 cannabinoid constituents identified, and the postulated role of the minor phytocannabinoids in modulating these effects ('the entourage effect') remains to be fully elucidated ([@bibr103-0269881118760662]; [@bibr147-0269881118760662]). This points to a limitation in the epidemiological evidence where potency of cannabinoid constituents is infrequently considered, with marked variation noted between sites ([@bibr130-0269881118760662]; [@bibr187-0269881118760662]) and marked variation between actual and labelled cannabinoid content ([@bibr23-0269881118760662]; [@bibr181-0269881118760662]). A further significant limitation in the epidemiological evidence is in the varying definition for 'cannabis user' -- for example, whether users are defined by lifetime or current use; and 'heavy use' -- for example whether this relates to frequency or duration of use ([@bibr99-0269881118760662]). Furthermore, whereas laboratory-based studies have established alternative pharmacodynamic profiles between methods of cannabinoid ingestion (inhaled, intravenous, oral) ([@bibr74-0269881118760662]; [@bibr135-0269881118760662]; [@bibr163-0269881118760662]), this has not been yet considered in relation to the risk of psychotic disorder or its relapse. Hence no firm conclusions can be drawn about this.

### Cannabis and psychosis risk {#section3-0269881118760662}

Much of the focus to date has been towards examining whether cannabis use is a risk factor for psychotic illness ([@bibr82-0269881118760662]). This has historically been complicated by the 'self-medication hypothesis'. This posits that individuals with psychosis use cannabis to alleviate symptoms (reverse causality), hence that psychosis predicts cannabis use and explains a proportion of the association ([@bibr52-0269881118760662]). However, evidence of a temporal relationship, with cannabis use preceding the onset of psychosis, has been credibly demonstrated in a number of studies ([@bibr112-0269881118760662]), which argues against the reverse causality hypothesis. For example, in a re-analysis of the Swedish conscript study, an increase in psychotic incidence in historical cannabis users continued to be reported over 5 years after the initial assessment of cannabis use ([@bibr200-0269881118760662]). Similar results of cannabis use preceding increases in psychosis risk have been shown in New Zealand, Dutch and British cohorts ([@bibr5-0269881118760662]; [@bibr58-0269881118760662]; [@bibr183-0269881118760662]). Structural equation modelling has further demonstrated ([@bibr53-0269881118760662]) that the association between cannabis use and psychosis reflects the effect of cannabis use on psychotic symptoms rather than the other way round, although another study that employed a sibling-pair design ([@bibr100-0269881118760662]) suggested that the relationship may be more nuanced. Evidence from McGrath et al. suggested that those who are vulnerable to developing psychosis might also be more likely to start using cannabis, which in turn may increase the likelihood of their developing a psychotic disorder subsequently.

Longitudinal studies have also demonstrated a dose-response relationship between cannabis use and psychosis risk: Moore and colleagues undertook a major meta-analysis which demonstrated an increased Odds Ratio (OR) of 1.41 for cannabis users (OR 2.09 in more frequent users) of developing a psychotic outcome ([@bibr112-0269881118760662]). It has been noted that the overall OR is small ([@bibr67-0269881118760662]), although a more recent meta-analysis also demonstrated an increased OR of 3.90 for most severe users compared with non-users ([@bibr99-0269881118760662]). It has been argued that the dose-related association between cannabis use and psychosis risk may not be related to a causal association, but may represent an attempt at self-medication of an impaired neurodevelopmental profile in the years preceding illness ([@bibr67-0269881118760662]). To our knowledge, in the absence of reported data from large longitudinal cohorts, this has yet to be tested directly. However, the literature appears to suggest that neurodevelopmental liability appears to be a less common feature in patients who develop psychosis and use cannabis (discussed below).

A further important consideration is a shared vulnerability for psychotic disorders and use of cannabis through genetic vulnerability or stress ([@bibr67-0269881118760662]; [@bibr82-0269881118760662]). An important methodological limitation of observational studies that precludes against definitive conclusions being drawn is inadequate adjustment for the plethora of potential confounders: around 60 different confounders have been identified, and Moore and colleagues noted that residual confounders can never be completely eliminated ([@bibr112-0269881118760662]). A more recent review noted that an increased risk of psychosis in cannabis users remains when extensive confounders are adjusted for (such as age, sex, substance misuse, tobacco use), although certain confounders such as childhood trauma and genetic variability have been more infrequently looked at ([@bibr59-0269881118760662]). Large-scale studies demonstrate higher polygenic risk of schizophrenia to be associated with cannabis, supporting shared genetic vulnerability, but this accounts for a small fraction of the variance of cannabis use overall (0.47--0.49%) ([@bibr132-0269881118760662]; [@bibr140-0269881118760662]). Evidence from studies that have used statistical modelling ([@bibr53-0269881118760662]) and sibling-pair design ([@bibr100-0269881118760662]) suggests that the association between cannabis use and psychosis is unlikely to be explained by residual confounding factors such as shared vulnerability (e.g. genetic) ([@bibr155-0269881118760662]) that may not have been measured in longitudinal studies.

It has been therefore argued that cannabis represents a component cause for enduring psychotic disorder, that is, by itself neither necessary nor sufficient to cause disorder but implicated in the patho-aetiology of illness alongside other factors which increase psychosis risk ([@bibr6-0269881118760662]; [@bibr59-0269881118760662]). One approach is to consider whether transition to psychosis occurs in enriched samples, that is, those at higher risk of developing disorder in cannabis users as opposed to non-users. This approach is made complicated by the fact that at least one study has shown that those who self-present at clinical high risk are likely to stop using cannabis due to the distressing nature of the symptoms ([@bibr179-0269881118760662]). Although earlier studies had not shown an association between cannabis use and psychosis transition ([@bibr8-0269881118760662]; [@bibr39-0269881118760662]), more recent larger studies considering abuse or cannabis-induced attenuated psychotic symptoms have shown an association between cannabis and psychosis transition ([@bibr7-0269881118760662]; [@bibr102-0269881118760662]), although in Auther et al. this only remains at the trend level (*p*=0.064) after adjusting for alcohol use.

Finally, a further argument against a causal association between cannabis and psychosis relates to the incidence of psychosis ([@bibr71-0269881118760662]). It has been demonstrated that, despite an increase in potency of cannabis use over several decades, this has not led to an expected increase in the incidence of psychotic disorders ([@bibr57-0269881118760662]; [@bibr79-0269881118760662]), thus rendering a causal association unlikely. This remains a contentious point -- some authors have pointed out that despite increasing rates of obesity, a well-established risk factor for cardiovascular health, cardiovascular health outcomes have improved in recent times in the Western world ([@bibr85-0269881118760662]). Thus the epidemiological relationship between risk factor and outcome does not hold if there is an intervening third factor (e.g. improved availability of cardiovascular treatments). Recently some data have emerged suggesting that psychotomimetic experiences in cannabis users, which may be a precursor to psychosis risk, lead to discontinuation of cannabis use, which may in turn offset risk of transition to psychosis in high-risk groups ([@bibr149-0269881118760662]; [@bibr179-0269881118760662]; [@bibr182-0269881118760662]).

### Cannabis use and psychotic relapse {#section4-0269881118760662}

In addition to increasing the risk of onset of psychosis, cannabis use also has an adverse effect on outcome in those who develop psychosis. Of the 50089 participants of the Swedish conscript study, 401 (0.8%) had schizophrenia-related inpatient admissions in the subsequent 34 years. Of those in whom baseline cannabis data were available, 78/357 (20%) had a history of cannabis use. This group had had more hospital admissions compared with never users over the 34-year period (10 vs. four) and had spent a year longer in hospital compared with the never users (547 days vs. 184) ([@bibr98-0269881118760662]).

Other studies confirm adverse prognostic features of cannabis use. In patients with an established psychotic illness, continued cannabis use has been shown to be associated with adverse outcomes. A recent meta-analysis using pooled data from over 16500 patients with psychosis, who were at various stages of psychotic illness, demonstrated that continued cannabis use is associated with greater risk of relapse, hospitalization and longer inpatient admissions ([@bibr154-0269881118760662]). Discontinuing cannabis use appeared to decrease the risk of relapse to a level that was similar to patients who had never used cannabis. That cannabis use at presentation with first-episode psychosis (FEP) is associated with increased risk of relapse subsequently was further independently confirmed by 5-year follow-up of over 2000 FEP patients in South London ([@bibr122-0269881118760662]). This study suggested that those with cannabis use at onset of FEP spent on average 35 additional days in hospital over 5 years compared with those without history of cannabis use. However, not all patients who develop psychosis following cannabis use continue using the drug following onset of their illness. This was investigated in a separate study, which demonstrated that outcomes are worse in those reporting frequent and continued use of high-potency cannabis ([@bibr154-0269881118760662]) compared with those who had stopped, also suggesting a dose-response relationship.

A further prospective study across five UK sites (*n*=1027) following FEP patients for a year after referral to Early Intervention Services also demonstrated poorer outcome in cannabis-using patients which remained after adjusting for other substance misuse ([@bibr162-0269881118760662]). However, the authors did note that they could not completely exclude the possibility that increases in symptomatology led to increases in use. Furthermore, all of these studies also did not adjust for treatment compliance. This is particularly important, as a recent meta-analysis has demonstrated that history of cannabis use may be associated with 150% increase in the risk of treatment non-adherence ([@bibr55-0269881118760662]), consistent with independent evidence ([@bibr158-0269881118760662]) as well as evidence that impaired treatment adherence may mediate the association between cannabis use and poor outcome in those with FEP ([@bibr159-0269881118760662]).

Similar to the association between cannabis use and psychotic onset, the association between cannabis use and psychotic relapse must adjust for a plethora of potential confounders, including tobacco smoking, other substance misuse, medication non-adherence, personality and genetic traits which may aggregate in the cannabis-using group. The difficulty in ensuring this across all studies relates to the limitations of observational methods in disentangling known and unknown confounders. Evidently, due to ethical reasons, one cannot administer cannabis in double-blind randomized controlled trials to determine psychosis outcome. However, recent evidence employing a quasi-experimental design within a longitudinal design demonstrates that alternative explanations and residual confounders do not fully explain the relationship between cannabis and psychotic relapse, and suggest that increased risk of relapse is contributed to by the cannabis itself ([@bibr155-0269881118760662], [@bibr156-0269881118760662], [@bibr157-0269881118760662]).In particular, this study demonstrated that even after controlling for the effect of the most important factors that vary over the course of illness and may potentially affect outcome (such as adherence to medication for psychosis and use of other illicit drugs following onset of psychosis), as well as for premorbid confounding factors that remained stable over the course of illness (such as shared familial and genetic vulnerability, personality traits, history of childhood trauma, duration of untreated psychosis, expressed emotion and cannabis use history before the onset of psychosis), cannabis use remained a significant risk factor relapse. By comparing periods of cannabis use with periods of no use within the same individual, this study demonstrated that both change in cannabis use status (e.g. from being an user to a non-user or vice versa) and change in the pattern of cannabis use (e.g. from intermittent use to more regular cannabis use) adversely affects outcome in established psychosis, suggesting the existence of a biological gradient (dose-response relationship). Furthermore, the authors were able to rule out the possibility of reverse causality by demonstrating that cannabis use status and change in pattern of cannabis use predicted subsequent relapse and not vice versa.

There is some evidence for poorer treatment response in cannabis-using patients. In an experimental study, D2 receptor antagonists have been shown to inadequately prevent psychotic symptoms induced by administration of THC to stable patients ([@bibr47-0269881118760662]). A systematic review suggests that conventional medications for psychosis (dopamine receptor antagonists) have some efficacy in psychotic patients with cannabis use, with some suggestion that clozapine, which is believed to have adjunctive non-dopaminergic action, is superior in treating psychotic symptoms and reducing cannabis cravings ([@bibr193-0269881118760662]). However, this was demonstrated in studies with small sample sizes and did not directly compare treatment response in cannabis-using and non-using groups. One study of 161 previously drug-naïve non-affective FEP patients administered olanzapine, risperidone or haloperidol over 6 weeks demonstrated poor treatment response and disorganization in cannabis users ([@bibr124-0269881118760662]). In a large naturalistic sample (*n*=2026) followed up to 5 years after presentation, cannabis use has been shown to be associated with an increased number of unique medications for psychosis prescribed, a proxy measure for decreased tolerability and poor treatment response in a naturalistic setting ([@bibr122-0269881118760662]). However, this study did not adjust for poor treatment compliance and other substance misuse. Future studies in this area should therefore ensure adequate measures of compliance to ensure a precise measurement of the effect of cannabis use on response to treatment.

Consequently one arrives at the conclusion that, although limitations in the epidemiological evidence still exist, there is something in the biological substance of exogenously administered phytocannabinoids which potentiates psychotic disorders. This relationship appears to be more well established for those with established psychotic disorders (i.e. relapse) than psychosis risk, for which debates about the extent of a causal link remain. Hence, for patients with established psychotic disorders, it seems that the time has come to move beyond debates about associations of cannabis and psychosis to developing an understanding of the underlying neurobiology in order to develop interventions that work.

Are cannabis-using and non-using patients different groups? {#section5-0269881118760662}
-----------------------------------------------------------

Why cannabis-using psychosis patients have a worse prognosis is as yet unclear. Emerging evidence suggests that cannabis-using psychosis patients may have distinct clinical, prognostic and neurocognitive features compared with non-users ([Table 1](#table1-0269881118760662){ref-type="table"}). A large meta-analysis including over 22500 patients has shown that patients who develop psychosis following a history of cannabis use present almost 3 years earlier, whereas alcohol does not have the same effect ([@bibr86-0269881118760662]). A further meta-analysis revealed that adjusting for tobacco use did not change this finding ([@bibr118-0269881118760662]).

###### 

Differences between cannabis-using patients and non-using patients with early psychosis.

![](10.1177_0269881118760662-table1)

                                                                                                                                                                                       Patients with early psychosis   
  --------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------- ------------------------------- ---
  Illness age of onset ([@bibr86-0269881118760662])                                                                                             22519                                  ↓                               ↑
  Risk of relapse ([@bibr154-0269881118760662])                                                                                                 16500                                  ↑                               ↓
  Duration hospital stay ([@bibr154-0269881118760662])                                                                                          16500                                  ↑                               ↓
  Hospital admissions ([@bibr98-0269881118760662]; [@bibr122-0269881118760662])                                                                 357 over 35 years; 2026 over 5 years   ↑                               ↓
  Medication used ([@bibr122-0269881118760662])                                                                                                 2026                                   ↑                               ↓
  Neurological soft signs ([@bibr13-0269881118760662]; [@bibr97-0269881118760662]; [@bibr108-0269881118760662]; [@bibr146-0269881118760662]);   264                                    ↓                               ↑
  Memory performance ([@bibr153-0269881118760662])                                                                                              3261                                   ↑                               ↓

Interestingly, poorer prognosis and younger age of onset in cannabis-using patients contrasts with the suggestion of their having a less impaired neurodevelopmental profile. Three lines of evidence converge to show this: (a) fewer neurological soft signs (NSS) in cannabis-using patients versus non-using patients ([@bibr13-0269881118760662]; [@bibr97-0269881118760662]; [@bibr108-0269881118760662]; [@bibr146-0269881118760662]); (b) improved neurocognitive performance in the cannabis-using group ([@bibr153-0269881118760662]; [@bibr169-0269881118760662]); and (c) neuroimaging and other neurobiological measures such as increased hippocampal volumes in the cannabis-using group, which has been shown in some studies ([@bibr41-0269881118760662]; [@bibr80-0269881118760662]), although not shown in all studies ([@bibr96-0269881118760662]); discussed in further detail in the second section.

### Neurological soft signs {#section6-0269881118760662}

Fewer NSS have been reported in FEP cohorts in heavy cannabis users. One study (*n*=92) demonstrated this in a group of daily cannabis users versus infrequent or non-existent use ([@bibr146-0269881118760662]). Although the cannabis-using group had a preponderance of weekly cocaine users (32/51), there remained significantly fewer NSS when this was adjusted for. A more recent French study (*n*=61) demonstrated similar findings in daily or dependent cannabis users as opposed to less frequent users when tobacco, alcohol but not other substance misuse had been adjusted for ([@bibr97-0269881118760662]), whereas a Tunisian cohort (*n*=61) found findings in the same direction after adjusting for tobacco and alcohol ([@bibr108-0269881118760662]). The difference between cannabis-using and non-using patients, with fewer NSS, does not appear to be limited to early psychosis and has been demonstrated in a cohort of chronic patients ([@bibr13-0269881118760662]). A further study of 112 patients, of whom 69 were followed up after 10 years, conversely did show increased NSS at presentation in cannabis-using patients, but showed neurocognitive sparing compared with non-users after 10 years ([@bibr169-0269881118760662]). This would argue against the suggestion of pre-existing differences and may suggest cannabis use has a protective role. However, given the evidence of increased neurocognitive impairment associated with cannabis use in non-clinical samples (see [@bibr92-0269881118760662]; [@bibr105-0269881118760662]; [@bibr153-0269881118760662]), this may be unlikely in clinical samples and such an interpretation requires further replication and should be considered with caution. Given the paucity of longitudinal data, further studies are needed before definitive conclusions can be drawn.

### Neurocognition {#section7-0269881118760662}

A meta-analysis of over 3200 patients with early psychosis showed better cognitive performance in cannabis-using patients in global memory, visual recall and recognition compared with those not using cannabis, with the authors suggesting that cannabis-using patients were a younger, less depressed and neurocognitively spared group ([@bibr153-0269881118760662]). Other meta-analyses have similarly found improved neurocognitive profile in patients who use cannabis ([@bibr133-0269881118760662]; [@bibr199-0269881118760662]). One explanation for this could be the higher abilities required for acquisition and use of cannabis. In line with this it has been argued that improved executive function in cannabis-using patients would equate to improved social cognition. However, this has not been conclusively shown and preliminary findings have yielded contradictory results ([@bibr4-0269881118760662]; [@bibr68-0269881118760662]).

Furthermore, the association between cannabis use and neurocognitive performance in the context of psychosis is not unidirectional, and recent studies have suggested a more nuanced view. One recent study of 268 FEP patients showed worse neurocognitive performance in cannabis-using patients, which was worse in those without a family history of psychosis compared with users with a family history ([@bibr62-0269881118760662]), whereas another major study (*n*=956) found worse outcomes in continued cannabis users, while lifetime users were neurocognitively spared ([@bibr106-0269881118760662]). While this may suggest an interaction between cannabis use and the propensity to develop psychotic disorder differentially affecting subgroups, further studies are required to disentangle the precise nature of this effect.

Taken together, for both NSS and neurocognition, the majority of evidence points towards decreased neurodevelopmental liability in cannabis users, although this is not unequivocal. Furthermore, this has been based upon mostly cross-sectional studies, hence causality cannot be established. These results require further replication in longitudinal studies to effectively disentangle the cannabis and psychosis interaction on neurological function.

Yet the phenotypic differences between cannabis-using patients and non-users suggest that cannabis-using patients may constitute a distinct group. This may be (i) due to the effect of cannabis itself; (ii) due to the effect of addiction or substance misuse on reward pathways; or (iii) this may represent cannabis-using patients having fewer pre-existing impairments and better cognitive abilities to start with. If cannabis users and non-users with psychosis are indeed distinct groups they may represent separate pathways to psychosis. Determining the biological underpinnings of such differences, particularly the neurochemical and neurophysiological abnormalities that may distinguish cannabis-using from non-using psychosis patients, may have implications in terms of unravelling potential alternative therapeutic targets in the cannabis-using group, a group with particularly worse outcomes.

II. Unravelling neurobiological underpinnings between groups {#section8-0269881118760662}
------------------------------------------------------------

In this and the following section we undertake a systematic review of neurobiological and neurochemical differences specifically between cannabis and non-using patients with psychosis as well as those at increased risk of developing psychosis. Previous reviews have extrapolated findings from preclinical studies and/or reported on findings from non-psychotic cannabis users ([@bibr38-0269881118760662]; [@bibr116-0269881118760662]; [@bibr135-0269881118760662]; [@bibr150-0269881118760662]; [@bibr185-0269881118760662]), or have not adequately differentiated cannabis from other substance misuse ([@bibr1-0269881118760662]). In this section we focus on neurobiological measures (imaging and electrophysiological) in cannabis-using and non-using groups within the psychosis spectrum. In the third section we focus on neurochemical differences between groups.

### Method {#section9-0269881118760662}

A systematic search strategy was undertaken with PubMed between November and December 2017 (last full search 28 December 2017), with results restricted to human studies. Search terms were: (cannabis OR marijuana) AND (psychosis OR schizo\*) AND (MRI OR fMRI OR dopamine OR GABA OR glutam\* OR CB1 OR CB1R OR endocannabinoid OR postmortem OR autopsy OR autoradiography OR EEG OR evoked potential OR event related potential OR ERP). Articles were selected by the following criteria: (a) human studies; (b) relevant to neurobiological measures of psychosis; (c) including a cannabis-using group of patients with psychotic disorder (P-C); (d) including a non-cannabis-using group of patients with psychotic disorder (P-NC). Some 325 articles were identified on initial search and abstracts reviewed. Identified articles were hand-searched for further articles and relevant references for reviews in the area ([@bibr1-0269881118760662]; [@bibr116-0269881118760662]; [@bibr135-0269881118760662]; [@bibr150-0269881118760662]). In total, 70 articles were identified for the final review.

Data extracted from all selected articles included: (a) measure of interest; (b) numbers in psychosis cannabis-using and non-using groups; (c) numbers in control cannabis-using and non-using groups; (d) whether longitudinal or cross-sectional study; (e) psychosis population of interest (whether early psychosis, chronic psychosis, diagnosis of interest, or whether high-risk cohort); (f) relevant findings. To assess risk of bias the following were extracted: (a) definition of cannabis use; (b) limitations of article; and (c) confounders considered in the study design -- namely alcohol, tobacco, other recreational substance misuse and exposure to medications for psychosis. If data were not available from the main manuscript, supplementary data were searched. A confounder was noted as having been considered in any of the following instances: (a) the said confounder had been excluded at the inclusion/exclusion stage; *or* (b) as demonstrated in the data provided there were no statistically significant baseline differences between P-C (group with psychosis or high risk of psychosis who use cannabis) and P-NC (group with psychosis or high risk of psychosis who do not use cannabis) for the given confounder; *or* (c) the confounder was adjusted for statistically (for example using regression methods); *or* (d) the confounder was demonstrated not to have an effect on the measure of interest; *or* (e) a sensitivity analysis was undertaken to consider the effect of the results when the confounder of interest was removed. Because of the heterogeneity of outcome measures, this systematic review represents a qualitative synthesis of the data and meta-analysis was not undertaken.

### Results {#section10-0269881118760662}

Of the 70 articles extracted (numbers of patients given are approximate as we have tried to account for overlapping cohorts), eight studies considered structural magnetic resonance imaging (MRI) studies in high-risk states for psychosis (P-C *n*=261; P-NC *n*=539); 16 considered structural MRI studies in the first 5 years of psychosis (P-C *n*=378; P-NC *n*=383); eight considered structural findings after the first 5 years (P-C *n*=131; P-NC *n*=116); six considered functional MRI findings (P-C *n*\>55; P-NC *n*\>36); 14 considered other neurobiological measures including peripheral findings and electrophysiology (P-C *n*=208; P-NC *n*=378); 12 considered the endocannabinoid system (P-C *n*=152; P-NC *n*=287); five considered the dopamine system (P-C *n*=44 ; P-NC *n*=59); three studies to date have investigated the glutamate system (P-C *n*=40; P-NC *n*=65); and two studies have investigated the GABAergic system (P-C *n*=24; P-NC *n*=28). Collectively, therefore, this systematic review collates data for over 1253 participants for P-C and 1843 participants for P-NC (including both patients and those at high risk). The results of the complete systematic review can be seen in [Tables 2](#table2-0269881118760662){ref-type="table"} and [3](#table3-0269881118760662){ref-type="table"}. Below we discuss the salient features. Where relevant, in the discussion that follows additional studies have been cited for contextual purposes.

###### 

Characteristics of included studies in patients/risk of psychosis comparing cannabis users (P-C) with non-users (P-NC): Neurobiological differences.

![](10.1177_0269881118760662-table2)

  Study                                                                                            Method                                                                                                                                  Measure                                                                                                                                                    Population                                                                                                                                                         Cannabis use definition                                                                                                                                                               *N*                                                                                                                             Findings                                                                                                              Limitations                                                                                                                         Confounders considered:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --- --- ----- ---
  ***(a) MRI Studies in high-risk states***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  [@bibr189-0269881118760662]                                                                      MRI - **2 years longitudinal**                                                                                                          Thalamus & mediotemporal volumes                                                                                                                           High genetic risk of schizophrenia                                                                                                                                 Cannabis use during intervening 2 years between scans                                                                                                                                 25                                                                                                                              32                                                                                                                                                                                                                                                                                  Bilateral thalamic volume loss P-C vs. P-NC. Amygdala-Hippocampal volume change non-significant                                                                                                                                                                                                                                    No HC comparator group. Unclear how many progressed to psychotic disorder                                                                                                                                       Y   Y   N/A   Y
  [@bibr191-0269881118760662]                                                                      MRI (cross-sectional)                                                                                                                   Volumetric analysis of ventricles, prefrontal lobe, amygdala-hippocampal complex and thalamic nuclei                                                       High genetic risk of schizophrenia                                                                                                                                 P-C: Regular use; P-NC: Use of ≤3 occasions/lifetime                                                                                                                                  73                                                                                                                              69                                                                                                                    15                                                                                                                                  20                        Cannabis use correlated with increased ventricular size (particularly 3rd ventricle) in risk group. This relationship does not hold in control group                                                                                                                                                                               OR of progression to psychotic disorder 3.18, P-C vs. P-NC. Unclear whether this correlates with imaging findings                                                                                               Y   Y   N/A   Y
  [@bibr64-0269881118760662]                                                                       *Discussed below (see (a)(ii))*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  [@bibr172-0269881118760662]                                                                      MRI (cross-sectional)                                                                                                                   Regional grey matter (GM)                                                                                                                                  At-risk mental state (ARMS)                                                                                                                                        Ever use. Analysis undertaken by cannabis intake (occasions per year)                                                                                                                 19                                                                                                                              8                                                                                                                     14                                                                                                                                  13                        Heavier cannabis use associated with reduced GM volume in prefrontal cortex. No distinct effects in ARMs vs. HCs                                                                                                                                                                                                                   Small study. Does not establish functional correlate of GM loss                                                                                                                                                 Y   Y   Y     Y
  [@bibr190-0269881118760662]                                                                      MRI tensor-based morphometry, **2 years longitudinal**                                                                                  Regional grey matter (GM)                                                                                                                                  High genetic risk of schizophrenia                                                                                                                                 Cannabis use during intervening 2 years between scans                                                                                                                                 23                                                                                                                              32                                                                                                                                                                                                                                                                                  Reduction in right anterior hippocampus and left superior frontal gyrus P-C vs. P-NC                                                                                                                                                                                                                                               No HC comparator group. Unclear how many progressed to psychotic disorder                                                                                                                                       Y   Y   N/A   Y
  [@bibr139-0269881118760662]                                                                      *Discussed below (see (a)(ii))*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  [@bibr29-0269881118760662]                                                                       Resting state fMRI functional connectivity (cross-sectional)                                                                            Thalamic functional connectivity                                                                                                                           Clinical high-risk (NAPLS-2 cohort)                                                                                                                                Rated by severity of use, frequency of use, age of first use and whether early or late onset (cut off age 15)                                                                         50                                                                                                                              112                                                                                                                   92                                                                                                                                  13                        Significant correlation between age of onset of cannabis use in CHR and thalamic hyper-connectivity with sensory motor cortex (significant on left, trend level on right)                                                                                                                                                          Unclear how many progress to psychotic disorder                                                                                                                                                                 Y   N   N     Y
  [@bibr30-0269881118760662]                                                                       MRI (cross-sectional)                                                                                                                   Hippocampus, amygdala, thalamus volumes                                                                                                                    Clinical high-risk (NAPLS-2 cohort)                                                                                                                                Use in the last month                                                                                                                                                                 132                                                                                                                             387                                                                                                                                                                                                                                                       204                       No difference P-C vs. P-NC after adjustment for tobacco and alcohol                                                                                                                                                                                                                                                                No metric for lifetime/cumulative exposure. No HC-C group                                                                                                                                                       Y   N   Y     Y
  ***(b) Structural MRI studies in patients (within 5 years of first episode)***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  [@bibr31-0269881118760662]                                                                       MRI (cross-sectional)                                                                                                                   Regional brain volumes                                                                                                                                     Recent-onset schizophrenia, schizoaffective, schizophreniform                                                                                                      DSM IV cannabis abuse/dependence                                                                                                                                                      27                                                                                                                              20                                                                                                                                                                                                                                                                                  No difference total brain volume, caudate, cerebellar volume. Decreased left/right asymmetry P-C vs. P-NC                                                                                                                                                                                                                          P-C significantly younger than P-NC (21.13 years vs. 27.61)                                                                                                                                                     N   Y   Y     N
  [@bibr175-0269881118760662]                                                                      MRI (cross-sectional)                                                                                                                   Prefrontal brain volumes                                                                                                                                   Recent-onset schizophrenia, schizoaffective, schizophreniform                                                                                                      DSM IV cannabis abuse/dependence                                                                                                                                                      20                                                                                                                              31                                                                                                                                                                                                                                                        56                        P-C significantly decreased anterior cingulate grey matter vs. P-NC                                                                                                                                                                                                                                                                Manual outlining of frontal brain regions                                                                                                                                                                       Y   Y   Y     N
  [@bibr198-0269881118760662]                                                                      MRI (cross-sectional)                                                                                                                   Volumetric measure of superior temporal gyrus, amygdala-hippocampal complex, cingulum                                                                      Recent-onset schizophrenia, schizoaffective disorder recently admitted to hospital                                                                                 Lifetime abuse                                                                                                                                                                        20                                                                                                                              21                                                                                                                                                                                                                                                                                  P-C vs. P-NC: no effect on brain morphology between groups                                                                                                                                                                                                                                                                         P-C all used cannabis, also reported: stimulants (35%), opiates (10%), cocaine (40%), hallucinogens (5%), alcohol (10%)                                                                                         N   N   Y     N
  [@bibr10-0269881118760662]                                                                       MRI (cross-sectional)                                                                                                                   Dorsolateral prefrontal cortex, hippocampus, posterior cingulate, cerebellum, intracranial volume                                                          Schizophrenia, schizoaffective, schizophreniform                                                                                                                   Lifetime use vs. never use                                                                                                                                                            15                                                                                                                              24                                                                                                                                                                                                                                                        42                        Right posterior cingulate showed trend for reduced GM volume P-C vs. P-NC. No difference for DLPFC, cerebellum, hippocampus, whole brain volume                                                                                                                                                                                    8/15 (53%) P-C group had poly-substance use                                                                                                                                                                     N   Y   Y     N
  [@bibr128-0269881118760662]                                                                      MRI -- Diffusion tensor imaging (cross-sectional)                                                                                       Fractional anisotropy (FA) & markers of white matter integrity                                                                                             Recent-onset schizophrenia/schizoaffective/schizophreniform                                                                                                        P-C: Cannabis use \< age of 17; P-NC No cannabis use \< 17                                                                                                                            24                                                                                                                              11                                                                                                                                                                                                                                                        21                        FA higher in patients using before 17 than controls in anterior capsule, fasciculus uncinatus, frontal white matter                                                                                                                                                                                                                Small numbers. Requires further replication and correlation with function                                                                                                                                       Y   Y   Y     N
  [@bibr44-0269881118760662]                                                                       MRI: High resolution structural and diffusion tensor imaging (cross-sectional)                                                          WM density, fractional anisotropy                                                                                                                          DSM IV schizophrenia, male                                                                                                                                         At least weekly for 6 months of life. Early-Onset Cannabis use ≤15; Late Onset Cannabis Use≥17                                                                                        18                                                                                                                              8                                                                                                                                                                                                                                                         10                        Reduced FA and WM density in left posterior corpus collosum, right occipital lobe, left temporal lobe, for P-NC compared with early-onset users                                                                                                                                                                                    Small groups size -- 8 early-onset users and 10 late-onset users                                                                                                                                                N   N   Y     N
  [@bibr75-0269881118760662]                                                                       MRI: voxel-based morphometry and diffusion tensor imaging (cross-sectional)                                                             Regional brain volumes and fractional anisotropy. Neurocognitive IQ (measured by WASI)                                                                     Adolescents with DSM IV schizophrenia                                                                                                                              More than 3 days/week for 6 months. All participants last use ≥28 days prior                                                                                                          16                                                                                                                              16                                                                                                                                                                                                                                                        28                        P-C vs. P-NC widespread grey matter loss in mediotemporal, insular, cerebellum, occipital and ventral striatum areas. Decreased FA in brainstem, internal capsule, corona radiata, superior and inferior longitudinal fasciculus                                                                                                   Age of onset younger in P-NC vs. P-C - may represent atypicality of adolescent schizophrenia                                                                                                                    N   Y   Y     N
  [@bibr36-0269881118760662]                                                                       MRI (cross-sectional)                                                                                                                   Cerebellar grey and white matter volumes                                                                                                                   First-episode schizophrenia                                                                                                                                        Juvenile cannabis use. Average age of first use (PC-C) 15.1, (HC-C) 15.5; lifetime doses (PC-C) 22700, (HC-C) 17900                                                                   6                                                                                                                               13                                                                                                                    17                                                                                                                                  19                        Dose-related decreased GM in cerebellum for HC-C vs. HC-NC. Decreased GM changes in P vs. HC. No interaction of cannabis use with diagnosis on GM cerebellar changes                                                                                                                                                               Small P-C group                                                                                                                                                                                                 N   Y   N     N
  [@bibr84-0269881118760662]                                                                       MRI (cross-sectional)                                                                                                                   Volumes: frontal, temporal, parietal, subcortical, cortical thickness, surface area, cognitive measures                                                    Early-onset schizophrenia                                                                                                                                          Lifetime cannabis abuse/dependence. Excluded positive urine test                                                                                                                      13                                                                                                                              35                                                                                                                    16                                                                                                                                  51                        PC-NC vs. HC-NC and HC-C vs. HC-NC decreased left superior parietal cortex, relative sparing in PC-C. PC-C vs. PC-NS: GM left thalamus volume reduced                                                                                                                                                                              Excluded current users                                                                                                                                                                                          N   N   Y     N
  [@bibr152-0269881118760662]                                                                      MRI (cross-sectional)                                                                                                                   Regional brain volumes & neurocognitive testing                                                                                                            DSM IV schizophrenia                                                                                                                                               Lifetime cannabis abuse/dependence                                                                                                                                                    30                                                                                                                              24                                                                                                                                                                                                                                                                                  P-C vs. P-NC higher GM density in left middle frontal gyrus. Significantly correlated with Continuous Performance Task (indexes working memory and attention, *r*=0.681)                                                                                                                                                           Needs further replication                                                                                                                                                                                       Y   Y   Y     Y
  [@bibr41-0269881118760662]                                                                       MRI (cross-sectional)                                                                                                                   Grey matter and lateral ventricle volumes & neurocognition (WMAT, COWAT, digit span)                                                                       First-episode psychosis                                                                                                                                            Lifetime history of at least 3 times per month for 1 year                                                                                                                             28                                                                                                                              78                                                                                                                                                                                                                                                        80                        P-NC vs. HC-NC decreased grey matter but in P-C vs. P-NC less grey matter loss in left middle frontal gyrus, left hippocampus, left parahippocampal gyrus. P-C vs. P-NC fewer attentional and executive deficits                                                                                                                   P-C younger and more time in full time education than P-NC                                                                                                                                                      Y   Y   Y     N
  [@bibr66-0269881118760662]                                                                       MRI: voxel-based morphometry and diffusion tensor imaging & neurocognitive testing (TAP, WMS-R) (cross-sectional)                       Grey matter volume & tract-based spatial statistics & fractional anisotropy                                                                                First-episode psychosis                                                                                                                                            1\. Heavy Use: near daily use for at least 1 year prior to presentation; 2. Light Use\>lifetime use 10 times, less than heavy use; 3. Considered as non-user if used up to 10 times   33                                                                                                                              17                                                                                                                                                                                                                                                                                  No difference between P-C and P-NC on voxel-based morphometry or DTI analysis or neurocognitive measures. No difference between heavy vs. light use                                                                                                                                                                                Small size ?underpowered                                                                                                                                                                                        N   Y   Y     N
  [@bibr139-0269881118760662]                                                                      MRI (cross-sectional)                                                                                                                   Grey matter volumes in cingulate cortex                                                                                                                    At-risk mental state and first-episode psychosis                                                                                                                   Current cannabis use                                                                                                                                                                  Pts:8 ARMS:14                                                                                                                   Pts:15 ARMS:22                                                                                                                                                                                                                                                                      Negative effect of cannabis use on posterior cingulate cortex and left anterior cingulate for both FEP and ARMS                                                                                                                                                                                                                    Small sample size. Manual segmentation -- high interrater reliability                                                                                                                                           Y   N   Y     N
  [@bibr96-0269881118760662]                                                                       MRI & MRS (cross-sectional)                                                                                                             Volumetric analysis: hippocampus, amygdala, caudate, putamen, thalamus, corpus callosum; MRS metabolites (N-acetyl-aspartate) indexes neuronal integrity   First-episode schizophrenia                                                                                                                                        Cannabis abuse                                                                                                                                                                        29                                                                                                                              20                                                                                                                                                                                                                                                        30                        Psychosis patients volume loss left hippocampus and amygdala vs. controls. P-C vs. P-NC larger mid-sagittal area of corpus callosum. P-C had higher left putamen N-acetyl aspartate/choline                                                                                                                                        No functional correlate. Limited information on cannabis use                                                                                                                                                    N   N   N     N
  [@bibr51-0269881118760662]                                                                       MRI **Longitudinal - 18 month follow-up**                                                                                               Cortical thinning & neurocognitive (D-KEFS Tower Test)                                                                                                     Early-onset schizophrenia/schizoaffective/schizophreniform                                                                                                         Lifetime cannabis abuse/dependence at baseline                                                                                                                                        11                                                                                                                              17                                                                                                                    17                                                                                                                                  34                        No significant main effect for psychosis, but main effect for cannabis use disorder -- widespread cortical thinning. No significant effect for cannabis use disorder × psychosis interaction                                                                                                                                       Small P-C group. Needs replication in a larger cohort                                                                                                                                                           Y   N   N     Y
  [@bibr80-0269881118760662]                                                                       MRI (cross-sectional)                                                                                                                   Surface-based analysis of a priori brain regions                                                                                                           DSM IV psychotic disorders (male patients only)                                                                                                                    DSM IV cannabis abuse/dependence                                                                                                                                                      80                                                                                                                              33                                                                                                                                                                                                                                                        84                        P-C vs. P-NC: increased putamen enlargement in P-C. Patients vs. controls: smaller volumes amygdala, putamen, insula, parahippocampus, fusiform gyrus                                                                                                                                                                              Did not correct for smoking or medication                                                                                                                                                                       Y   Y   Y     Y
  ***(c) Structural MRI Studies in Patients (after 5 years of first episode)***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  [@bibr136-0269881118760662]                                                                      MRI -- **5 years longitudinal**                                                                                                         Ventricle size and total grey matter (GM) volume change                                                                                                    Recent-onset schizophrenia                                                                                                                                         Ever cannabis use during scan interval (5 years)                                                                                                                                      19                                                                                                                              32                                                                                                                                                                                                                                                        31                        Larger ventricular size and reduced GM in direction: P-C\>P-NC\>HC. P-C vs. P-NC less pronounced symptomatic improvement                                                                                                                                                                                                           No HC-C group to disentangle psychosis × cannabis interaction                                                                                                                                                   Y   Y   Y     N
  [@bibr137-0269881118760662]                                                                      MRI -- **5 years longitudinal**                                                                                                         Cortical thickness                                                                                                                                         Recent-onset schizophrenia                                                                                                                                         Ever cannabis use during scan interval (5 years)                                                                                                                                      19                                                                                                                              32                                                                                                                                                                                                                                                        31                        P-C vs. P-NC no baseline difference. Over 5 years increased cortical thinning in DLPFC, ACC and left occipital lobe                                                                                                                                                                                                                Does not establish functional correlate of cortical thinning                                                                                                                                                    Y   Y   Y     N
  [@bibr64-0269881118760662]                                                                       MRI (cross-sectional)                                                                                                                   Cortical thickness                                                                                                                                         DSM IV psychotic disorders, siblings; controls                                                                                                                     1 Subjects who have never used cannabis; 2 subjects who have used 1--39 times (moderate); 3 subjects who have used ≥40 times (heavy)                                                  52 pts; 33 siblings                                                                                                             28 pts; 53 siblings                                                                                                   21                                                                                                                                  48                        Patients with heavy use had lower cortical thickness than those with no use. Same relationship for siblings but not for controls                                                                                                                                                                                                   Needs replication in larger samples. No function correlate of diminished cortical thickness                                                                                                                     N   Y   Y     N
  [@bibr167-0269881118760662]                                                                      MRI (cross-sectional)                                                                                                                   Cerebellar grey matter and white matter volume                                                                                                             Schizophrenia, right-handed male                                                                                                                                   Long-term heavy cannabis use (near daily use for ≥9 years)                                                                                                                            8                                                                                                                               9                                                                                                                     15                                                                                                                                  16                        No group differences in GM volume. Direction of WM volume: HC-NC\>P-NC\>HC-C\>P-C                                                                                                                                                                                                                                                  Small groups P-C and P-NC                                                                                                                                                                                       Y   Y   N     Y
  [@bibr166-0269881118760662]                                                                      MRI (cross-sectional)                                                                                                                   Hippocampal shape analysis                                                                                                                                 Schizophrenia                                                                                                                                                      Long-term regular use; \>60000 doses last 10 years                                                                                                                                    8                                                                                                                               9                                                                                                                     15                                                                                                                                  16                        Hippocampal shape changes in each group vs. HC-NC with greatest changes in P-C vs. H-C                                                                                                                                                                                                                                             Small P-C group. Chronic patient group. No functional correlation                                                                                                                                               Y   Y   N     Y
  [@bibr165-0269881118760662]                                                                      MRI (cross-sectional)                                                                                                                   Surface-based representations of globus pallidus (GP), striatum, thalamus and working memory                                                               DSM IV Schizophrenia                                                                                                                                               DSM IV lifetime cannabis abuse/dependence                                                                                                                                             15                                                                                                                              28                                                                                                                    10                                                                                                                                  44                        Morphological shape differences observed in cannabis groups (P-C vs. P-NC and HC-C vs. HC-NC) in striatum, GP and thalamus. Morphological changes more pronounced in P-C than HC-C. For both P-C and HC-C striatal and thalamic changes correlated with WM deficits and younger age of CUD diagnosis                               Cannabis use group not had substance misuse diagnosis in 6 months prior to the study. Cross-sectional -- need longitudinal follow-up                                                                            Y   Y   Y     Y
  [@bibr164-0269881118760662]                                                                      MRI (cross-sectional)                                                                                                                   Surface-based analysis of hippocampus, episodic memory (logical memory II test)                                                                            DSM IV schizophrenia                                                                                                                                               DSM IV cannabis abuse/dependence 6 months previously                                                                                                                                  15                                                                                                                              28                                                                                                                    10                                                                                                                                  44                        Effect of shape changes by cannabis use disorder 'cannabis-like shape'. Separate changes on shape of hippocampus by schizophrenia 'schizophrenia-like shape'. P-C group demonstrated increasing cannabis shape changes with increasing duration of cannabis use disorder. P-C vs. P-NC trend level worse on episodic memory task   Prolonged period of abstinence for cannabis users (at least 6 months)                                                                                                                                           Y   Y   Y     Y
  [@bibr144-0269881118760662]                                                                      MRI -- diffusion tensor imaging (cross-sectional)                                                                                       Fractional anisotropy & markers of white matter integrity                                                                                                  First-episode psychosis (ICD-10 diagnosis confirmed using OPCRIT+)                                                                                                 Lifetime history of cannabis use. Further analyses undertaken on other parameters (age of first use, potency of use, frequency of use)                                                37                                                                                                                              19                                                                                                                    22                                                                                                                                  21                        Higher potency cannabis associated with disturbed corpus callosum microstructure in both patients with psychosis and cannabis users                                                                                                                                                                                                No functional correlate described                                                                                                                                                                               N   N   N     N
  ***(d) functional MRI studies in patients***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  [@bibr90-0269881118760662]                                                                       fMRI -- dichotic auditory perception task                                                                                               BOLD activation of default mode network and effort mode network                                                                                            DSM IV schizophrenia                                                                                                                                               Lifetime cannabis use. Current users excluded                                                                                                                                         13                                                                                                                              13                                                                                                                                                                                                                                                                                  P-C vs. P-NC: increased activation in regions involved in effort mode network and decreased activation in default mode network                                                                                                                                                                                                     Unconventional method of indexing network activity. Cannot extend work to current users                                                                                                                         N   N   Y     N
  [@bibr27-0269881118760662]                                                                       fMRI -- emotional memory task                                                                                                           BOLD activation in emotional picture recognition                                                                                                           DSM IV schizophrenia, males                                                                                                                                        Cannabis use disorder (abuse/dependence) diagnosed in last 6 months                                                                                                                   14                                                                                                                              14                                                                                                                                                                                                                                                        21                        P-C vs. P-NC: medial prefrontal cortex activation increased in emotional picture recognition                                                                                                                                                                                                                                       Small study. Needs further replication in larger samples                                                                                                                                                        N   Y   Y     N
  [@bibr131-0269881118760662] (from same group as [@bibr27-0269881118760662]?same patient group)   fMRI -- visuospatial task and mental rotation                                                                                           Regional BOLD activation                                                                                                                                   DSM IV schizophrenia, males                                                                                                                                        Cannabis use disorder (abuse/dependence) diagnosed in last 6 months                                                                                                                   14                                                                                                                              14                                                                                                                                                                                                                                                        21                        P-C vs. P-NC: preserved activation left superior parietal gyrus (decreased in P-NC). No difference in task performance P-C vs. P-NC                                                                                                                                                                                                Small study. Needs further replication in larger samples                                                                                                                                                        N   Y   Y     N
  [@bibr93-0269881118760662]                                                                       fMRI attentional bias using a classical Stroop task and cannabis Stroop task after 4 weeks of treatment with risperidone or clozapine   Stroop task performance and BOLD activation. Classical Stroop indexes selective attention, Cannabis stroop to index attentional bias                       DSM IV schizophrenia, schizoaffective, schizophreniform disorder, male gender                                                                                      Cannabis abuse/dependence                                                                                                                                                             28                                                                                                                              8                                                                                                                                                                                                                                                         19                        No difference P-C vs. P-NC in performance in Stroop task. P-C vs. P-NC no difference in regional activation for classical Stroop. Greater activation in left and right amygdala for P-C vs. P-NC                                                                                                                                   Small P-NC group ?underpowered. Also main purpose of study not to compare P-C vs P-NC groups but to compare risperidone vs. clozapine. Confounders not adjusted for outcomes of interest                        N   N   N     N
  [@bibr123-0269881118760662]                                                                      Resting state fMRI functional connectivity (cross-sectional)                                                                            Dorsolateral prefrontal cortex functional connectivity (DLPFC-fc) & neurocognitive testing (WAIS III and others)                                           Psychosis, unaffected siblings and controls                                                                                                                        Ever use vs. never use                                                                                                                                                                Patients with psychosis (*n*=73); Unaffected siblings (*n*=83); Controls (*n*=72); Numbers not clearly stated by cannabis use   No significant group × cannabis interaction for DLFPC-fc and no significant interaction with neurocognitive testing   Most patients on medication. Effect of this unclear. Use of current use maybe more sensitive to change than lifetime cannabis use   N                         N                                                                                                                                                                                                                                                                                                                                  Y                                                                                                                                                                                                               N             
  [@bibr94-0269881118760662]                                                                       Cue reactivity to cannabis and neutral images fMRI                                                                                      Regional BOLD activation to cannabis images                                                                                                                DSM IV schizophrenia/schizoaffective/schizophreniform                                                                                                              Lifetime cannabis use disorder (based on CIDI)                                                                                                                                        30                                                                                                                              8                                                                                                                                                                                                                                                         20                        P-C vs. P-NC greater activation to cannabis images in right amygdala and left and right thalamus. *Also* 4 weeks of clozapine superior to risperidone in reducing craving in P-C                                                                                                                                                   Designed to compare clozapine vs. risperidone rather than to compare P-C vs. P-NC. Small P-NC group                                                                                                             N   N   N     N
  ***(e) Other neurobiological measures***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  [@bibr77-0269881118760662]                                                                       Blood (cross-sectional)                                                                                                                 Serum nerve growth factor (NGF) (cross-sectional)                                                                                                          DSM IV schizophrenia, presenting as inpatient, medication naïve                                                                                                    \>0.5 g on average per day for at least 2 years. Positive UDS excluded                                                                                                                21                                                                                                                              76                                                                                                                    11                                                                                                                                  61                        P-C NGF levels mean=412.9; P-NC 26.3; HC-C 20.1; HC-NC 33.1. Significantly raised in P-C group                                                                                                                                                                                                                                     Small numbers in cannabis-using group. P-C onset of psychosis younger than P-NC                                                                                                                                 Y   Y   Y     N
  [@bibr76-0269881118760662]                                                                       Blood (cross-sectional)                                                                                                                 Serum brain derived neurotrophic factor (BDNF) (cross-sectional)                                                                                           DSM IV schizophrenia, medication naïve                                                                                                                             \>0.5g on average per day for at least 2 years. Positive UDS excluded                                                                                                                 35                                                                                                                              102                                                                                                                   11                                                                                                                                  61                        P-C BDNF levels mean=17.7; P-NC 13.1; HC-C 13.1; HC-NC 13.2. Highest in P-C group, significant vs. H-C and P-NC                                                                                                                                                                                                                    P-C onset of psychosis younger than P-NC. Needs replication                                                                                                                                                     Y   Y   Y     N
  [@bibr78-0269881118760662]                                                                       Blood (including follow-up of [@bibr77-0269881118760662])                                                                               Serum nerve growth factor (NGF) (cross-sectional)                                                                                                          DSM IV schizophrenia, treated with medication for psychosis for 4 weeks                                                                                            \>0.5 g on average per day for at least 2 years. Positive UDS excluded                                                                                                                42                                                                                                                              66                                                                                                                    24                                                                                                                                  51                        No statistically significant difference between groups (i.e. NGF levels raised in P-C had normalized). Decrease across patient groups in NGF levels from [@bibr77-0269881118760662]. Also small cohort replicated [@bibr77-0269881118760662] baseline results                                                                      Needs replication                                                                                                                                                                                               Y   Y   Y     N
  [@bibr12-0269881118760662]                                                                       Eye movement tracking (cross-sectional)                                                                                                 Fixation clustering, saccadic gaze                                                                                                                         DSM IV cannabis-induced psychosis (CIP) vs. first-episode schizophrenia based on SCID                                                                              Based on diagnosis of CIP (see limitations)                                                                                                                                           6                                                                                                                               11                                                                                                                                                                                                                                                        22                        Differences noted in visual scan paths. More restricted visual features in P-C patient with increased fixation clustering such that P-C\>P-NC\>HC-C. Alterations in saccadic gaze (frequency, amplitude, velocity) for P-C vs. HC-NC in altered pattern compared with P-NC vs. HC-NC                                               Small study and needs replication. Definition of P-C and P-NC in study based on CIP vs. schizophrenia. Three patients with schizophrenia (in P-NC) had used cannabis before developing schizophrenia            N   N   N     N
  [@bibr142-0269881118760662]                                                                      EEG with auditory stimuli (cross-sectional)                                                                                             P50 Sensory gating                                                                                                                                         DSM IV schizophrenia/schizoaffective                                                                                                                               History of chronic cannabis abuse. All users abstinent ≥28 days                                                                                                                       15                                                                                                                              12                                                                                                                    11                                                                                                                                  18                        No difference between P-C and P-NC. In HC-C P50 sensory deficit correlated with number of years with daily consumption. Relationship not present in other groups                                                                                                                                                                   Small sample size ?underpowered. There is a difference of circa 10% between P-C vs. P-NC but not significant                                                                                                    Y   Y   N     N
  [@bibr141-0269881118760662]                                                                      EEG with auditory stimuli (cross-sectional)                                                                                             Mismatch negativity (MMN)                                                                                                                                  DSM IV schizophrenia/schizoaffective                                                                                                                               Chronic cannabis use: at least 5 days per week for at least 1 year by self-report. All users abstinent ≥28 days                                                                       27                                                                                                                              26                                                                                                                    32                                                                                                                                  34                        Frequency MMN amplitude P-NC\<P-C\<HC-C\<HC-NC                                                                                                                                                                                                                                                                                     No functional correlation shown. Requires replication                                                                                                                                                           Y   Y   Y     Y
  [@bibr160-0269881118760662]                                                                      Electrophysiology with auditory stimuli (cross-sectional)                                                                               Prepulse Inhibition (PPI)                                                                                                                                  Schizophrenia/schizoaffective                                                                                                                                      Lifetime use                                                                                                                                                                          20                                                                                                                              44                                                                                                                    34                                                                                                                                  32                        Alterations of PPI in all groups vs. HC-C such that reduced PPI in P-NC vs. HC-NC but this is diminished in P-C vs. HC-NC. Authors suggest cannabis may have medicating effect on impaired attentional modulation for patients and have similar effect on attentional modulation for patients and healthy controls                 Preponderance of other substance abuse/dependence in last 12 months in P-C group (60%)                                                                                                                          N   N   Y     Y
  [@bibr127-0269881118760662]                                                                      EEG with auditory stimuli (cross-sectional)                                                                                             Mismatch Negativity (MMN) and P3a latency                                                                                                                  Early psychosis, DSM IV psychotic disorders                                                                                                                        History of past or current cannabis use at least monthly for one year                                                                                                                 22                                                                                                                              22                                                                                                                                                                                                                                                        21                        For MMN amplitude: P-NC\<P-C\<HC-NC. For MMN latency: P-C\>P-NC and HC-NC. For P3a amplitude at frontal electrode: P-C\<P-NC and latency P-C\>P-NC                                                                                                                                                                                 No functional correlate identified                                                                                                                                                                              Y   Y   N     N
  [@bibr184-0269881118760662]                                                                      EEG with auditory oddball paradigm (cross-sectional)                                                                                    N100, N200, P200, P300                                                                                                                                     Ultra-high risk                                                                                                                                                    History of use ≥5 times/lifetime. Use in last month                                                                                                                                   19                                                                                                                              29                                                                                                                    21                                                                                                                                  29                        No significant differences between P-C and P-NC                                                                                                                                                                                                                                                                                    Gender differences between groups (18% female P-C; 45% female P-NC). Although tobacco use was adjusted for, other recreational drug use not accounted for                                                       Y   Y   Y     N
  [@bibr32-0269881118760662]                                                                       Electrophysiology -- EEG and facial electromyography to visual stimuli of natural and cannabis rewards (cross-sectional)                Late positive potential (LPP), facial electromyography, skin conductance. Follow-up after 1 month for cannabis usage                                       DSM IV schizophrenia/schizoaffective                                                                                                                               Active cannabis use disorder in past 1 month vs. no cannabis use in last 3 months (P-NC)                                                                                              20                                                                                                                              15                                                                                                                    20                                                                                                                                  15                        P-C show blunted responses to natural rewards but spared response to cannabis stimulus. LPP in P-C predicts cannabis usage at 1 month                                                                                                                                                                                              Cannabis images prepared specifically for this task and not validated in previous tasks                                                                                                                         N   Y   Y     Y
  [@bibr65-0269881118760662]                                                                       EEG with somatosensory evoked potential (cross-sectional)                                                                               N20, P25                                                                                                                                                   Ultra-high risk (UHR) assessed by structured interview for prodromal symptoms and high risk (HR) for schizophrenia assessed by schizophrenia proneness interview                                                                                                                                                                                         HR 13; UHR 12                                                                                                                   HR 36; UHR 61                                                                                                         3                                                                                                                                   42                        P-C vs. P-NC: in both HR and UHR groups cannabis users showed higher N20-P25 source strength than non-users. Not calculated in HC due to small numbers of HC-C                                                                                                                                                                     Small cannabis arms. Possible effect of confounding variables (see right)                                                                                                                                       N   N   N     N
  [@bibr196-0269881118760662]                                                                      Electrophysiology with auditory stimuli (cross-sectional)                                                                               Prepulse inhibition (PPI) and prepulse facilitation (PPF)                                                                                                  At-risk mental state                                                                                                                                               Urine drug sample positive                                                                                                                                                            6                                                                                                                               18                                                                                                                    5                                                                                                                                   18                        PPI: HC-C vs. HC-NC increased PPI, P-C vs. P-NC decreased PPI; PPF: No group × substance use interaction                                                                                                                                                                                                                           Small numbers of cannabis participants. UDS only indicates recency of use                                                                                                                                       N   Y   Y     Y
  [@bibr113-0269881118760662]                                                                      Electrophysiology with auditory stimuli (cross-sectional)                                                                               Prepulse inhibition (PPI)                                                                                                                                  First-episode psychosis, on treatment (assessed by SCID for DSM IV)                                                                                                Lifetime cannabis abuse/dependence (assessed by SCID), currently abstinent                                                                                                            21                                                                                                                              14                                                                                                                                                                                                                                                        22                        PPI: at 30 ms reduced PPI for P-C vs. HC-NC and P-NC vs. HC-NC. At 60 ms reduced PPI for P-NC vs. HC-NC but not for P-C vs. HC-NC. At 120 ms no difference between groups                                                                                                                                                          No assessment of alcohol or other drug use. Although all had been on pharmacotherapy cumulative doses not matched                                                                                               N   N   Y     Y
  [@bibr143-0269881118760662] *(some overlap of participants with* [@bibr142-0269881118760662])    EEG to auditory novelty and oddball paradigms (cross-sectional)                                                                         P300                                                                                                                                                       Schizophrenia                                                                                                                                                      Chronic cannabis use: at least 5 days per week for at least 1 year by self-report. All users abstinent ≥28 days                                                                       20                                                                                                                              20                                                                                                                    20                                                                                                                                  20                        Different effects of cannabis use on patients and controls. Unadjusted: Early novelty P300 HC-NC\>HC-C\>P-NC\>P-C. Late novelty P300 HC-NC\>HC-C\>PC-NC\~--P-C. Parietal oddball HC-NC\>HC-C\>P-NC\>P-C                                                                                                                            No significant diagnosis interaction for early novelty p300 and oddball paradigm remained when nicotine and alcohol use entered as covariates. Significant difference between illicit drug use between groups   Y   N   Y     Y

*(a) MRI studies in high-risk groups (genetic, familial, clinical high risk)*.

*(b) MRI structural in patients with psychosis (including volumetric, morphometry and shape analysis, diffusion tensor imaging) first 5 years*.

*(c) MRI structural in patients with psychosis (including volumetric, morphometry and shape analysis, diffusion tensor imaging) after 5 years*.

*(d) Functional MRI studies in patients with psychosis*.

*(e) Other neurobiological measures (EEG, eye-tracking)*.

P-C: Psychosis/at-risk patients with cannabis use; P-NC: Psychosis/at-risk patients without cannabis use; HC-C: Non-psychosis controls with cannabis use; HC-NC: Non-psychosis controls without cannabis use; ETOH: Alcohol; AP: medication for psychosis; Tob: Tobacco.

###### 

Characteristics of included studies in patients/risk of psychosis comparing cannabis users (P-C) with non-users (P-NC): Neurochemical differences.
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  Study                                                                                          Method                                                                                                                                             Measure                                                                                                                     Population                                                                                                                                                                     Cannabis use definition                                                                                        *N*             Findings   Limitations                                                         Confounders considered:                                                                                                                                                                                                                                                                                                                                              
  ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------- --------------- ---------- ------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- --- --- --- ---
  ***(A) Endocannabinoid system***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  [@bibr43-0269881118760662]                                                                     Post-mortem autoradiography                                                                                                                        \[3H\]CP-55940 to index CB1 receptor density at dorsolateral prefrontal cortex, caudate-putamen and temporal lobe regions   Schizophrenia assessed after psychologist and psychiatrist case notes review using diagnostic instrument for brain studies (DIBS)                                              THC in blood at time of death                                                                                  5               9          4                                                                   9                                                                                        Increased DLPFC binding in patients vs. controls. Increased binding in caudate-putamen in cannabis groups independent of whether patients or controls   Small numbers. Did not adjust for key confounders (see right)                                           N   N   N   N
  [@bibr201-0269881118760662]                                                                    Post-mortem autoradiography                                                                                                                        \[3H\]SR141716A to index CB1 receptor density binding at anterior cingulate cortex                                          DSM III/DSM IV schizophrenia using case notes review using SCAN and DIBS                                                                                                       Lifetime ever use                                                                                              5               5                                                                              9                                                                                        No difference P-C vs. P-NC. Patients increased CB1 receptor binding compared with controls                                                              Small group size                                                                                        N   N   Y   N
  [@bibr111-0269881118760662]                                                                    Peripheral blood (cross-sectional)                                                                                                                 Fatty acid levels in blood                                                                                                  Schizophrenia treated with clozapine                                                                                                                                           Ever used. Last use ≥6 months ago                                                                              6               6                                                                                                                                                                       In cannabis users only: arachadonic acid correlated with total fatty acid. Linoliec acid correlated with stress                                         Small size; Discontinued users                                                                          N   Y   Y   N
  [@bibr87-0269881118760662]                                                                     Cerebrospinal fluid (CSF) (cross-sectional)                                                                                                        Anandamide levels                                                                                                           Schizophrenia                                                                                                                                                                  High frequency in cannabis group: ≥20 times per life. Low frequency in non-cannabis group: ≤5 times per life   22              25         26                                                                  55                                                                                       P-NC markedly higher anandamide in CSF than P-C. No difference between HC and HC-NC                                                                     Needs replication                                                                                       N   N   Y   N
  [@bibr45-0269881118760662]                                                                     Post-mortem autoradiography                                                                                                                        \[3H\]SR141716A and \[3H\]CP-55940 both to index CB1 receptor density at superior temporal gyrus                            DSM IV schizophrenia using case notes review using SCAN and DIBS                                                                                                               Not clear                                                                                                      4               4          8 non-psychiatric controls -- unclear if any cannabis use history   P-C vs. P-NC no difference between groups. No difference between patients vs. controls   Small numbers. Insufficiently clear about cannabis use history                                                                                          N                                                                                                       N   Y   N   
  [@bibr49-0269881118760662]                                                                     Post-mortem immunocytochemistry                                                                                                                    CB1 receptor mRNA in dorsolateral prefrontal cortex (Brodmann area 9)                                                       Schizophrenia/ schizoaffective                                                                                                                                                 Not clear                                                                                                      7               16                                                                             23                                                                                       No difference between P-C and P-NC. Reduction of around 10--15% in CB1 receptor transcript expression in patients vs. controls                          Study not designed to determine difference of P-C vs. P-NC. Tested as a possible confounding variable   N   Y   Y   N
  [@bibr50-0269881118760662] *Includes 14 patients and 14 HCs from* [@bibr49-0269881118760662]   Post-mortem immunocytochemistry                                                                                                                    CB1 receptor protein expression in dorsolateral prefrontal cortex (Brodmann area 46)                                        DSM IV Schizophrenia/schizoaffective using case notes review and structured interview with relative. Controls: Controls with no psychiatric history (NP) and depressed (DEP)   Lifetime history of cannabis use                                                                               6               15         0 NP, 3 DEP                                                         26 NP, 7 DEP                                                                             P-C vs. P-NC no significant difference between groups. Reduction of around 19--23% in CB1 receptor density in patients with psychosis vs. controls      Study not designed to determine difference of P-C vs. P-NC. Tested as a possible confounding variable   N   Y   Y   N
  [@bibr72-0269881118760662]                                                                     Structural MRI, cognitive assessment (WAIS subscales) by CB1 receptor genotype and cannabis interaction (cross-sectional)                          White matter & WAIS subscales                                                                                               Schizophrenia patients, P-C arranged by CB1 receptor genotype (12 tagged SNPs)                                                                                                 Cannabis abuse or dependence                                                                                   52              183                                                                                                                                                                     Three CB1 receptor polymorphisms associated with decreased WM volume. One also associated with decreased processing speed and attention in P-C          Needs replication in larger cohort. Possible confounding from other substance use                       Y   Y   Y   N
  [@bibr120-0269881118760662] *(from same sample as* [@bibr72-0269881118760662])                 Structural MRI by MAPK14 genotype and CB1 receptor and cannabis interaction (cross-sectional)                                                      White matter                                                                                                                Schizophrenia patients, P-C arranged by MAPK14 Receptor genotype (nine tagged SNPs)                                                                                            Cannabis abuse or dependence                                                                                   52              183                                                                                                                                                                     MAPK14 and CB1 receptor specific alleles associated with small white matter brain volume in heavy cannabis use. Independent and additive effect         As [@bibr72-0269881118760662]. Also no functional correlate of WM loss demonstrated                     Y   Y   Y   N
  [@bibr34-0269881118760662]                                                                     PET (cross-sectional)                                                                                                                              \[18F\]MK-9470 mSUV (indexes CB1 receptor)                                                                                  Schizophrenia                                                                                                                                                                  Ever use. Last use for all participants ≥6 months ago                                                          35              32                                                                             12                                                                                       Patients with a history of heavy cannabis use no significant difference in binding vs. medium, low or never use                                         Not designed to test P-C vs P-NC                                                                        N   N   N   N
  [@bibr188-0269881118760662] *(same participant group as* [@bibr49-0269881118760662]            Post-mortem autoradiography                                                                                                                        \[11C\]OMAR binding (indexes CB1 receptor)                                                                                  Schizophrenia/ schizoaffective                                                                                                                                                 Not clear                                                                                                      7               14                                                                             21                                                                                       \[11C\]OMAR binding did not differ between P-C vs. P-NC                                                                                                 Study not designed to determine difference of P-C vs. P-NC. Tested as a possible confounding variable   N   N   N   N
  [@bibr138-0269881118760662]                                                                    PET (cross-sectional)                                                                                                                              \[11C\]OMAR VT (indexes CB1 receptor)                                                                                       Male Schizophrenia                                                                                                                                                             Ever use. Lifetime cannabis use disorder excluded. 1/25 patients with recent use                               16              7          Total 18 HC. Lifetime use unclear                                   No significant correlations between cannabis use and VT                                  Not designed to test P-C vs. P-NC                                                                                                                       N                                                                                                       N   N   N   
  ***(b) Dopamine system***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  [@bibr42-0269881118760662]                                                                     Post-mortem autoradiography                                                                                                                        \[3H\]Mazidol for DAT; Tyrosine Hydroxylase                                                                                 Schizophrenia                                                                                                                                                                  Blood test +ve                                                                                                 5               9          4                                                                   10                                                                                       No significant difference between CBS users and non-users                                                                                               Small sample. Limited cannabis information                                                              N   N   Y   N
  [@bibr28-0269881118760662]                                                                     Peripheral blood (cross-sectional)                                                                                                                 Plasma homovanillic acid                                                                                                    Inpatient FEP vs. inpatient non-psychosis                                                                                                                                      Urine test +ve                                                                                                 5               15                                                                             18                                                                                       P-C group elevated HVA levels vs. P-NC and others (*p*=0.001)                                                                                           Small sample. Limited cannabis information                                                              N   N   N   N
  [@bibr148-0269881118760662]                                                                    SPECT (cross-sectional)                                                                                                                            \[123I\]IBZM striatal/frontal ratio to index D2/D3 receptor availability                                                    Untreated FEP patients                                                                                                                                                         Use 3 units/day for last 3 months (*n*=14)                                                                     14              23                                                                             18                                                                                       No significant difference between P-C and P-NC                                                                                                          Used S/F ratio but frontal binding may be altered in cannabis use                                       N   Y   Y   N
  [@bibr83-0269881118760662]                                                                     PET: 8 mg inhaled THC vs. placebo Acute challenge on dopamine function (interventional)                                                            \[18F\] Fallypride displaced                                                                                                Psychosis patients, first-degree relatives of patients, healthy controls                                                                                                       Self-report ever use                                                                                           8 pts 7 rel's              9                                                                                                                                                            THC induced significant striatal displacement of fallypride in patients and relatives but not controls                                                  No comparison between P-C and P-NC                                                                      Y   Y   Y   Y
  [@bibr109-0269881118760662]                                                                    PET: stress task to induce dopamine release (cross-sectional)                                                                                      \[11C\]PHNO displaced                                                                                                       Clinical high risk                                                                                                                                                             Use at least 3 times/week                                                                                      12              12                                                                                                                                                                      Decreased displacement in P-C group and increased in P-NC group in striatum                                                                             Unable to determine whether blunted dopamine release is marker of cannabis use or addiction             N   Y   Y   Y
  \(c\) Glutamate system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  [@bibr141-0269881118760662]                                                                    See [Table 2](#table2-0269881118760662){ref-type="table"} (e) (Mismatch Negativity believed to index glutamatergic function via NMDA receptor)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  [@bibr127-0269881118760662]                                                                    *See [Table 2](#table2-0269881118760662){ref-type="table"} (e) (Mismatch Negativity believed to index glutamatergic function via NMDA receptor)*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  [@bibr145-0269881118760662]                                                                    Magnetic resonance spectroscopy (cross-sectional)                                                                                                  Glutamate medial prefrontal cortex & neurocognitive assessment (MATRICS battery)                                            Early psychosis and healthy controls                                                                                                                                           Current cannabis use                                                                                           18              17                                                                             33                                                                                       Decreased glutamate in P-C vs. P-NC. Impaired working memory P-C vs. P-NC                                                                               Neuro-cognitive impairment in P-C rather than sparing. ?atypical sample. Requires further replication   Y   N   Y   Y
  ***(d) GABAergic system (indexed through cortical inhibition)***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  [@bibr197-0269881118760662]                                                                    Transcranial Magnetic Stimulation (cross-sectional)                                                                                                Short-interval cortical inhibition (SICI), intracortical facilitation (ICF)                                                 First-episode schizophrenia                                                                                                                                                    P-C: lifetime use of ≥20 times per lifetime; P-NC Lifetime use of ≤5 times                                     12              17                                                                                                                                                                      Reduced SICI and enhanced ICF for P-C vs. P-NC indicating GABAergic deficit and intracortical disconnectivity                                           SICI and ICF not direct measures of GABA-A. No comparison with HC groups                                N   Y   Y   N
  [@bibr63-0269881118760662]                                                                     Transcranial magnetic stimulation (cross-sectional)                                                                                                SICI/ICF                                                                                                                    Schizophrenia/schizoaffective disorder                                                                                                                                         DSM IV cannabis dependence                                                                                     12              11         10                                                                  13                                                                                       Increased SICI for PC vs. P-NC indicating increased GABA-A mediated inhibition, reduced SICI HC-C vs. HC-NC. No significant difference for ICF          SICI and ICF not direct measures of GABA-A                                                              Y   Y   Y   N

*(a) Endocannabinoid System*.

*(b) Dopamine System*.

*(c) Glutamate System*.

*(d) GABAergic System*.

P-C: Psychosis/at-risk patients with cannabis use; P-NC: Psychosis/at-risk patients without cannabis use; HC-C: Non-psychosis controls with cannabis use; HC-NC: Non-psychosis controls without cannabis use; ETOH: Alcohol; AP: medication for psychosis; Tob: Tobacco.

### Evidence from studies in electrophysiology and other neurobiological measures {#section11-0269881118760662}

In a series of early studies, Jockers-Scherubl and colleagues demonstrated markedly elevated neurotrophins in untreated cannabis-using patients with psychosis compared with both non-using patients and cannabis-using controls: serum nerve growth factor (NGF) and brain derived neurotrophic factor on initial admission ([@bibr77-0269881118760662], [@bibr76-0269881118760662]). Baseline NGF elevation was replicated in a follow-up study, and furthermore the elevation was noted to normalize following 4 weeks on medication treatment for psychosis ([@bibr78-0269881118760662]). These studies raise the possibility of distinct neuronal damage in the cannabis-using psychosis group, with neurotrophins as a state-dependent marker, although these results were not specific only to cannabis, as a mixed group of poly-substance misuse also demonstrated elevated neurotrophin levels. Although intriguing, these studies do not necessarily implicate neurotrophin elevation in the pathway of psychotic disorder. Of note there were small numbers of cannabis controls, and it is possible that elevated levels rescinded after decrease in use after inpatient admission rather than treatment.

A number of distinct electrophysiological alterations have also been noted in P-C versus P-NC indicating pre-attentional, attentional and reward cue deficits. Although one study demonstrated no differences between cannabis-using and non-using patients, in P50 sensory gating ([@bibr142-0269881118760662]), differences have been demonstrated in prepulse inhibition (PPI) with relative sparing of the diminished PPI amplitude seen in P-NC; ([@bibr113-0269881118760662]; [@bibr160-0269881118760662]); reduced P300 amplitudes for P-C versus P-NC to novelty and oddball auditory stimuli ([@bibr143-0269881118760662]), modulation of mismatch negativity (MMN) ([@bibr127-0269881118760662]; [@bibr141-0269881118760662]) and altered late positive potential to reward cues such that there appears to be blunting of response to natural but not cannabis visual cues in the P-C group ([@bibr32-0269881118760662]). MMN is believed to index glutamatergic function and is discussed further below (see III(iii)). Taken together, these indicate neurophysiological abnormalities in the P-C group neither accounted for fully by psychosis (P-NC group) or cannabis use (HC-C group). There appears to be some evidence for modulation in clinical high-risk groups of PPI: one study has paradoxically shown that PPI is increased in cannabis use verses healthy controls but decreased in at-risk mental state subjects ([@bibr196-0269881118760662]). Other studies have failed to elicit differences between P-C and P-NC in somatosensory evoked N20, P25 ([@bibr65-0269881118760662]), auditory oddball N100, N200, P200 and P300 ([@bibr184-0269881118760662]).

One further body of work has found PPI deficits in cannabis-induced psychotic disorder intermediate between healthy controls and those of schizophrenia with cannabis use. These studies were not included because of the lack of a P-NC group; however, they have been used to argue a neurobiological basis to a differentiation between cannabis-induced psychotic disorder (CIPD) and schizophrenia with cannabis use ([@bibr114-0269881118760662], [@bibr115-0269881118760662]). Further evidence for this comes from a small study demonstrating restrictions in visual field and alterations in saccadic gaze from P-C versus controls as opposed to patients with schizophrenia versus controls ([@bibr12-0269881118760662]). However, to date there is limited work to determine whether CIPD is a distinct entity to other psychotic disorders complicated by use of cannabis.

### Neuroimaging approaches {#section12-0269881118760662}

1.  *1. MRI in high-risk states*

Two main cohorts have reported on structural MRI measures in those at high risk who use cannabis and who do not. The Edinburgh High Risk Study recruited first-degree family members of patients. Cross-sectional and longitudinal analysis demonstrated cannabis to be associated with loss of brain volume and subcortical structures including thalamic, mediotemporal and frontal areas ([@bibr189-0269881118760662], [@bibr191-0269881118760662], [@bibr190-0269881118760662]). These were a non-clinical cohort (i.e. non-treatment seeking) and with limited healthy control cannabis users it is not possible to disentangle the effects of psychosis liability from cannabis-induced changes which would be expected in the general population. A number of smaller studies in high-risk samples have supported regional grey matter loss associated with heavier cannabis use (cingulate cortex, prefrontal cortex, cortical thickness) ([@bibr64-0269881118760662]; [@bibr139-0269881118760662]; [@bibr172-0269881118760662]). In the largest cohort -- the North American Prodrome Longitudinal Study (NAPLS) -- evaluating clinical high-risk groups there was noted to be no difference between cannabis users (defined as use in the last month) in hippocampal, amygdala, and thalamic volumes and thalamic connectivity, although there was a correlation between younger age of onset and thalamic connectivity with the sensory motor cortex ([@bibr29-0269881118760662], [@bibr30-0269881118760662]).

1.  *2. Structural MRI in the first 5 years of psychotic disorder*

There also appears to be differences detectable by neuroimaging approaches between cannabis-using and non-using patients in the first 5 years of psychotic disorder. Broadly speaking, given that both psychosis and cannabis use are known to be associated with atrophic changes and functional deficits compared with healthy non-using controls, there could alternative explanations to neurobiological differences between patients who use cannabis and those who do not: (a) there could be no difference between the groups (the null hypothesis); (b) there could be evidence of increased deficit or impairment in the P-C group compared with the P-NC group which may be accounted for by deleterious effects of cannabis use (i.e. an additive interaction of cannabis × psychosis); (c) there could be decreased deficit or impairment in the P-C group compared with the P-NC group (i.e. a sparing interaction of cannabis × psychosis).

In line with the null hypothesis, some studies have failed to find structural differences between groups ([@bibr31-0269881118760662]; [@bibr66-0269881118760662]; [@bibr198-0269881118760662]). Although these studies have their limitations of small sample sizes hence possibly being underpowered, they are no less than others. Others have found increased impairment in cannabis-using patients: increased grey matter loss in the cingulum ([@bibr10-0269881118760662]; [@bibr139-0269881118760662]; [@bibr175-0269881118760662]) and cerebellum ([@bibr36-0269881118760662]); whereas younger age of onset is associated with white and grey matter changes ([@bibr75-0269881118760662]; [@bibr128-0269881118760662]) and disruption of cortical maturation patterns ([@bibr51-0269881118760662]).

As against those, other studies have reported fewer grey matter ([@bibr152-0269881118760662]) and white matter deficits ([@bibr44-0269881118760662]) in patients who use cannabis, or with mixed findings ([@bibr84-0269881118760662]). Some larger, more recent studies have similarly found evidence that P-C may have an altered neurobiological profile in early psychosis, not simply explained by the deleterious effects of cannabis use. Cunha et al. undertook MRI imaging in 28 cannabis-using patients with FEP, 78 non-cannabis-using patients with FEP and 80 healthy controls. Users were significantly younger than non-users, more likely to be male and better educated. There was preservation of grey matter volumes in medial temporal areas and the prefrontal cortex in cannabis users as opposed to controls ([@bibr41-0269881118760662]). Increased hippocampal volume in cannabis-using patients versus non-using patients was also demonstrated by Malchow and colleagues in a series of 47 FEP patients, 20 of whom were cannabis users and 30 healthy controls. Again, the cannabis-using group was more likely to be male and significantly younger. They were prescribed significantly more medication for psychosis at the time of scan, although cumulative exposure was matched ([@bibr96-0269881118760662]). A further study of 113 male age-matched FEP patients (80 cannabis users), and 80 healthy controls, showed the cannabis-using group to have parahippocampal (but not hippocampal), amygdyla and putamen enlargement ([@bibr80-0269881118760662]).

Collectively, there are varying findings from neuroimaging studies in early psychosis. The majority of studies indicate there are structural brain differences between cannabis-using patients and non-using patients. There are likely to be altered effects of cannabis on patients, with CB1 receptor-rich areas such as the cingulate particularly prone to atrophic change. As against this there is some evidence of sparing of brain regions such as mediotemporal or striatal regions. Which regions are affected or spared and the extent of these are likely to be a function of propensity to develop psychosis, patterns of cannabis use and duration and age of first use. Currently, the functional correlates and clinical significant of these brain differences remain to be fully elucidated.

1.  *3. Structural MRI after the first 5 years of psychotic disorder*

In contrast to the conflicting evidence from studies in the early stages of psychosis, all studies after 5 years of psychotic disorder point towards degenerative changes in the cannabis-using patient group. These include two longitudinal studies of early psychosis followed up for 5 years ([@bibr136-0269881118760662], [@bibr137-0269881118760662]). Alterations observed in the P-C group include: increased ventricular size ([@bibr136-0269881118760662]), diminished cortical thickness ([@bibr64-0269881118760662]; [@bibr137-0269881118760662]), decreased grey ([@bibr136-0269881118760662]) and white matter ([@bibr144-0269881118760662]; [@bibr165-0269881118760662]; [@bibr167-0269881118760662]) and cannabis-induced alterations in the hippocampus ([@bibr164-0269881118760662]; [@bibr166-0269881118760662]), and change in surface shape of the striatum, globus pallidus and thalamus ([@bibr165-0269881118760662]). Taken together, degenerative changes secondary to cannabis use have been consistently found in both cross-sectional and longitudinal designs. Although there is a lack of functional correlation in many of these studies, in that atrophy does not necessarily equate with loss of function, one may speculate in conjunction with the studies discussed in the first section that continued cannabis use in patients with established psychotic disorder (after the first 5 years) is both associated with impaired function and neurobiology.

1.  *4. Evidence from functional MRI studies*

A few studies have examined neurophysiological differences between P-C and P-NC using functional MRI. In general, these studies have been modest in size, have studied varying paradigms and have been limited by a failure to include a cannabis-using control group and therefore require further replication. Nonetheless, they indicate differences between cannabis-using patients and those who do not use cannabis. These include differences in regional brain activation in emotional memory (prefrontal activation increased in P-C) ([@bibr27-0269881118760662]); functional connectivity of default mode and effort mode networks ([@bibr90-0269881118760662]), although an alternate resting state study showed no difference between groups ([@bibr123-0269881118760662]); differences in parietal activation in visuospatial tasks ([@bibr131-0269881118760662]); as well as differences in tasks used to interrogate addiction paradigms including attentional bias (greater amygdala activation in P-C) ([@bibr93-0269881118760662]) and cannabis cue reactivity (greater amygdyla and thalamic activation in P-C) ([@bibr94-0269881118760662]).

III. Unravelling neurochemical differences between groups {#section13-0269881118760662}
---------------------------------------------------------

1.  *1. Evidence from the endocannabinoid system*

The interaction of exogenous phytocannabinoids is through perturbation of the endocannabinoid system (the lipid signalling system that includes cannabinoid receptors and their naturally occurring ligands). The endocannabinoid receptor system comprises the CB1 and CB2 receptors, and G-protein coupled receptors with relative, but not complete segregation of CB1 receptors to the central nervous system, whereas CB2 receptor is expressed in the peripheral nervous system and believed to be involved in inflammatory processes ([@bibr91-0269881118760662]). These are not the only receptors involved in the endocannabinoid system, with evidence for implication of the TRPV1 receptor in peripheral sensory neurons, peroxisome proliferator-activated receptor gamma (PPAR-γ) in peripheral tissues and other G-protein coupled receptors such as GPR18 and GPR55([@bibr91-0269881118760662]; [@bibr126-0269881118760662]). Endogenous agonists that engage cannabinoid receptors are anandamide and 2-arachidonoyl glycerol (2AG); they are synthesized from lipid precursors ([@bibr91-0269881118760662]), hence cannot be stored in vesicles and are synthesized 'on demand' ([@bibr2-0269881118760662]; [@bibr104-0269881118760662]). For the most part, endogenous cannabinoids exert influence on pre-synaptic CB1 receptors to inhibit further neurotransmitter release (such as glutamate or GABA) via retrograde transmission, although there is also more recent evidence for non-retrograde and autocrine effects ([@bibr33-0269881118760662]). Degradation of anandamide and 2-AG occurs by the enzymes fatty acid amide hydrolyse (FAAH) and monoacylglycerol lipase (MAGL), respectively, and inhibition of degradation is related to prolonged endocannabinoid action ([@bibr104-0269881118760662]). Evidence of alteration in components of the endocannabinoid system unrelated to cannabis use in patients with psychosis (summarized by [@bibr3-0269881118760662]) suggests that modulation of the endocannabinoid system may be implicated in psychosis risk.

Most work on understanding the phytocannabinoid--psychosis interaction has focused on the CB1 receptor, due to its widespread distribution in the brain and implication in psychotomimetic mechanisms and risk. The CB1 receptor is believed to be the most widely G-protein coupled receptor in the brain ([@bibr173-0269881118760662]), with CB1 receptors distributed widely distributed throughout the brain in neocortical (cingulate gyrus, frontal cortex, secondary somatosensory), hippocampal, amygdalar, cerebellar and basal ganglia areas ([@bibr95-0269881118760662]; [@bibr125-0269881118760662]; [@bibr174-0269881118760662]). Delta-9-tetrahydrocannabinol (THC), the psychotomimetic constituent of cannabis, acts as a partial CB1 receptor agonist, with administration of THC leading to altered activation in a wide range of frontal (anterior cingulate, right inferior frontal gyri), parietal and limbic areas (midbrain, mediotemporal and ventro-striatal) ([@bibr20-0269881118760662], [@bibr14-0269881118760662], [@bibr15-0269881118760662], [@bibr17-0269881118760662]; [@bibr16-0269881118760662], [@bibr18-0269881118760662]; [@bibr24-0269881118760662]; [@bibr195-0269881118760662]). Increased potency of CB1 receptor agonism, either through increased THC potency or through full agonism of the CB1 receptor with synthetic cannabinoid receptor agonists has been noted to be associated with increased risk of developing psychosis and a more protracted course ([@bibr46-0269881118760662]; [@bibr119-0269881118760662]; [@bibr194-0269881118760662]). In contrast, CBD has been demonstrated to oppose the actions of THC ([@bibr21-0269881118760662], [@bibr14-0269881118760662], [@bibr19-0269881118760662]), is less well understood and is believed to act through a wide variety of actions including the antagonism of THC effects on the cannabinoid type 1 receptor, CB1 receptor inverse agonism, FAAH inhibition and 5HT1A activation ([@bibr121-0269881118760662]; [@bibr125-0269881118760662]). Particular interest has centred on cannabidiol as a potential treatment for psychosis, with one double-blind randomized controlled study showing non-inferiority to amisulpride after 28 days (*n*=39, cannabis users excluded), associated with concomitant increase in anandamide levels ([@bibr88-0269881118760662]), and another (*n*=88, baseline cannabis users=3/88) showing improved response versus placebo after 6 weeks as adjunctive therapy to patients' usual medication for psychosis ([@bibr101-0269881118760662]).

Differences between patients with psychotic disorders who use cannabis and those who do not are shown in [Table 3](#table3-0269881118760662){ref-type="table"}(a). Some evidence for alterations in endocannabinoid components has been demonstrated between groups. One study reported on anandamide cerebrospinal fluid (CSF) levels, finding low-frequency using patients (lifetime use less than five times) to have over 10-fold higher anandamide CSF levels compared with healthy control groups and non-using patients. The finding was not replicated in serum samples. The authors suggested that anandamide may act as a compensatory mechanism in acute psychosis, while frequent cannabis use could lead to a down-regulation of anandamide signalling to explain the results ([@bibr87-0269881118760662]). Another, albeit small, study (*n*=12) showed alterations in lipid precursors of endocannabinoids between users and non-users; however, given the small size this needs further replication ([@bibr111-0269881118760662]).

Most work in this area has been undertaken on the CB1 receptor. One early study showed increased CB1 receptor binding in the dorsolateral prefrontal cortex in P-C versus P-NC ([@bibr43-0269881118760662]). However, since then a number of studies have not demonstrated any differences between groups ([@bibr34-0269881118760662]; [@bibr45-0269881118760662]; [@bibr49-0269881118760662], [@bibr50-0269881118760662]; [@bibr138-0269881118760662]; [@bibr188-0269881118760662]; [@bibr201-0269881118760662]). These studies are mostly small in size and the two in vivo studies were not designed to test P-C versus non-PC ([@bibr34-0269881118760662]; [@bibr138-0269881118760662]); this notwithstanding, many of these studies were able to demonstrate altered CB1 receptor expression in patients compared with controls.

Finally, some work has demonstrated evidence of altered genotype by cannabis effects relating to white matter deficits. These found sensitivity for the following genotypes for the cannabinoid 1 receptor gene: rs12720071 to white matter damage and neurocognitive impairment, and for the MAPK14 gene (believed to be involved in CBR1 apoptosis induced by THC) for rs12199654. Both genotypes were demonstrated to have independent and additive effects ([@bibr72-0269881118760662]; [@bibr120-0269881118760662]).

1.  *2. Evidence from the dopamine system*

One would expect cannabis, a robustly implicated risk factor for psychosis, to affect dopamine signalling in the human brain. The dopamine hypothesis is the pre-eminent explanation for psychotic illness ([@bibr73-0269881118760662]). Indeed, in preclinical models THC has been shown to induce increases of dopamine neuron firing and dopamine levels in key mesolimbic areas including the ventral tegmental area as well as the nucleus accumbens and striatum ([@bibr35-0269881118760662]; [@bibr56-0269881118760662]; [@bibr60-0269881118760662]; [@bibr176-0269881118760662]). This relationship appears to be bidirectional, with preclinical evidence that dopamine modulates striatal endocannabinoid release ([@bibr61-0269881118760662]; [@bibr81-0269881118760662]).

Yet in human studies the evidence is far less conclusive. Studies using functional MRI in healthy volunteers have demonstrated that transient psychotic symptoms induced by experimental administration of THC is associated with its effects on activation in key brain areas rich in dopaminergic innervation, such as the striatum and midbrain ([@bibr20-0269881118760662], [@bibr14-0269881118760662], [@bibr15-0269881118760662]). However, a systematic review of data from 25 human studies which directly investigated various aspects of the dopamine signalling pathway in over 568 participants, of which 244 belonged to the cannabis or cannabinoid exposure group ([@bibr150-0269881118760662]), suggests a tenuous link between cannabinoid exposure and alterations in the dopaminergic signalling system. Even allowing for less precise estimations of dopamine in man, as compared with in animals, collectively current evidence suggests that while dopamine signalling alterations may be a consequence of cannabis use, the link may not be direct. As previously noted, there are limitations to extrapolating data from healthy controls to patients. Acute challenge studies of THC in healthy volunteers have revealed mixed results with no difference between groups ([@bibr11-0269881118760662]; [@bibr171-0269881118760662]) and striatal release noted in one study ([@bibr26-0269881118760662]) or increased dopamine transmission in post-hoc analysis ([@bibr25-0269881118760662]; [@bibr170-0269881118760662]). Most studies have not studied patients with psychotic disorder, but when patients with cannabis use have been included there appears to be evidence for blunting of dopaminergic response rather than sensitization, as may have been expected ([@bibr22-0269881118760662]; [@bibr180-0269881118760662]; [@bibr192-0269881118760662]), although a stress task found no difference between cannabis users and controls ([@bibr110-0269881118760662]).

Relatively few studies have looked specifically at patients with psychosis who use cannabis versus those who do not use. One study undertaking post-mortem autoradiography found no differences in dopamine active transport affinity (a marker of dopaminergic neurons) or tyrosine hydroxylase between P-C and P-NC; however, this was a small study and classified participants only on blood THC levels at time of death ([@bibr42-0269881118760662]). Another study looking at peripheral markers at admission found dopamine metabolites in the P-C group compared with other groups, but has not been replicated and was compromised by small sample sizes (P-C, *n*=5) ([@bibr28-0269881118760662]). Three studies have undertaken scintillography in clinical samples. Using SPECT one study found no differences in D2 receptor binding in first-episode patients who used cannabis and those who did not ([@bibr148-0269881118760662]). Interestingly, consistent with blunting shown in cannabis users (discussed above), in a clinical high-risk group administered a stress task, heavy cannabis users (use of at least three times per week) were shown to have blunted dopamine release compared with non-users ([@bibr109-0269881118760662]). One study has suggested that there may be differential responses based upon genetic risk of psychotic disorder ([@bibr83-0269881118760662]). Kuepper and colleagues administered THC or placebo to eight patients, seven relatives and nine healthy controls, finding significant striatal displacement of fallypride (indicating synaptic dopamine release) in patients and relatives but not controls. This may indicate that patients or those at genetic risk have an increased sensitivity to the effects of cannabis; further studies are required to replicate this and delineate the extent of this phenomenon.

1.  *3. Evidence from the glutamatergic and GABAergic systems*

If dopamine abnormalities do not fully explain psychosis linked to cannabis use, an alternate explanation must be sought. CB1 receptor activation, the mechanism through which THC induces psychotic symptoms under experimental conditions, mediates inhibition of glutamate and γ-aminobutyric acid (GABA) through retrograde transmission in cortical, hippocampal and midbrain regions ([@bibr103-0269881118760662]). While these may therefore seem valid alternative pathways, little work has been undertaken to date to determine whether glutamatergic/GABAergic abnormalities are associated with cannabis use in psychosis. Several lines of evidence indicate glutamatergic dysfunction in psychotic illness independent of cannabis exposure. These include: (1) drug-induced models with NMDA receptor antagonists ketamine and PCP producing schizophrenia-like psychosis; and (2) Magnetic resonance spectroscopy (MRS) studies indicating altered glutamatergic metabolites in psychosis patients compared with controls ([@bibr107-0269881118760662]).

To date there appears some suggestion that cannabis use, independent of psychosis, may be associated with perturbation of the glutamatergic system. Decreased glutamatergic indices in cortical and subcortical areas in cannabis users compared with non-users have been reported ([@bibr38-0269881118760662]). Furthermore, preclinical work has implicated cannabinoid receptor activation in the reduction of long-term potentiation of glutamatergic transmission through NMDA receptor hypofunction at the hippocampus, which is associated with deficits in learning and memory ([@bibr151-0269881118760662]). We are only aware of one study which has reported on glutamate levels in patients who use cannabis and those who do not ([@bibr145-0269881118760662]). Rigucci and colleagues found lower glutamatergic indices in the prefrontal cortex in cannabis-using versus non-using patients. Interestingly, in their sample the cannabis users were more rather than less cognitively impaired as compared with non-cannabis-using patients. Further studies are required to determine whether these results are replicable in other cohorts. MMN has also been used to interrogate glutamatergic perturbation, as it is well demonstrated that NMDA antagonists such as ketamine induce alterations in MMN ([@bibr9-0269881118760662]). As noted, two studies have indicated altered MMN in P-C, indicating possible underlying glutamatergic dysfunction ([@bibr127-0269881118760662]; [@bibr141-0269881118760662]). Glutamate may thus be a promising avenue for further investigation.

Evidence of GABAergic deficits mimicking psychotic-like symptoms and deficits in GABAergic markers in patients on post-mortem studies ([@bibr89-0269881118760662]) supports a GABAergic theory of schizophrenia. However, a meta-analysis of MRS GABA imaging has revealed no difference between schizophrenia patients and controls ([@bibr161-0269881118760662]). Interestingly, a recent challenge study did demonstrate enhanced psychotomimetic effects of synthetic THC when co-administered with iomazenil, a GABA antagonist ([@bibr134-0269881118760662]). This may suggest a role for the GABAergic system in inhibiting psychotic-like symptoms induced by THC. Nevertheless, there appears to be less support for a GABAergic in contrast to a glutamatergic alteration as a potential mechanism linking cannabis and psychosis. To date no studies have directly reported on GABAergic differences between P-C and P-NC. However, GABA function has been indexed by studies on cortical inhibition which is believed to be GABA-A-mediated ([@bibr168-0269881118760662]). The two studies undertaken to date have given opposing results ([@bibr63-0269881118760662]; [@bibr197-0269881118760662]) which may be due to differences in the definition of the cannabis-using group (dependence or use ≥20 times) or other methodological differences, and further work is required to determine the effect of cannabis use on the GABAergic system in psychosis.

### Future approaches {#section14-0269881118760662}

Collectively, there is therefore a compelling case for investigating glutamatergic indices in psychosis patients with cannabis use. Interaction with the GABAergic system also requires further elaboration. Future work should therefore investigate whether cannabis use is associated with alterations in glutamatergic and/or GABAergic indices. These can be investigated through MRS and single photon emission tomography (SPET) or positron emission tomography (PET) approaches. MRS is widely used in investigating both glutamate and GABA levels in psychosis, but is limited by its inability to differentiate between metabolic and neurotransmitter pools of glutamatergic markers ([@bibr129-0269881118760662]). PET/SPET have been limited by lack of available tracers; however, radioligands for both GABA and glutamate systems offer advantage of specificity and are amenable to dynamic challenge studies ([@bibr54-0269881118760662]). Advances in MRS image acquisition and radiotracer development hold promise for future research in this area ([@bibr54-0269881118760662]; [@bibr129-0269881118760662]).

Regarding the endocannabinoid system, particular promise may be related to the effects of cannabidiol. As yet no randomized controlled trial has determined whether there is an increased efficacy and acceptability of CBD as a medication for psychosis in cannabis users and the neurobiological mechanisms, including perturbation of the endocannabinoid system which may underpin this.

Imaging techniques may be applied to differentiate cannabis-using and non-using patients across the trajectory of illness, including clinical high-risk groups, unmedicated and medicated patients with early psychosis and patients with enduring illness. Longitudinal study design will likely help establish the precise relationship between cannabis use, alterations in the glutamate/GABA signal and outcome. Understanding the neurochemical mechanisms would enable alternative treatment strategies to be developed for this patient group, or may indeed point towards a 'endocannabinoid dysfunction pathway' to psychosis pathway, not fully explained by dopaminergic, glutamatergic or GABAergic changes.

**Declaration of conflicting interests:** The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding:** The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: MS and SB are funded through a Medical Research Council (UK) Clinical Research Training Fellowship to MS (MR/P001408/1). SB has been funded by the National Institute for Health Research (NIHR), UK through a Clinician Scientist award (NIHR-CS-11-001), Medical Research Council (MC_PC_14105) and also supported by the NIHR Biomedical Research Centre for Mental Health BRC Nucleus at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Psychology and Neuroscience, King's College London.

**Role of the funding source:** The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the MRC or the Department of Health. The funders had no role in the preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. All authors have approved the final version of the paper.

**ORCID iD:** Dr Sagnik Bhattacharyya ![](10.1177_0269881118760662-img1.jpg) <https://orcid.org/0000-0002-8688-8025>
